SRZN
NASDAQSurrozen Inc.
Surrozen Inc. (SRZN) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for SRZN, including 2 insider trades, 1 offering and 1 SEC filing. The most recent was published Oct 22, 2026.
SRZN rankings
Financial highlights
Full financials- Revenue, TTM
- $11.51M
- Revenue growth
- -8.8%
- Net income, TTM
- -$332.13M
- Net margin
- -2885.3%
- Free cash flow, TTM
- -$34.98M
- Cash
- $102.04M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks32+150%
2026-05-102026-11-01
Mix1490d
- Other6(43%)
- SEC Filings4(29%)
- Insider2(14%)
- Analyst1(7%)
- Offering1(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Surrozen Inc.4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Surrozen Inc.4 - Surrozen, Inc./DE (0001824893) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECSEC Form 8-K filed by Surrozen Inc.8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 MillionSOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the closing of the second and final tranche of its March 2025 private placement of securities. The second closing generated approximately $95.1 million in gross proceeds, before deducting placement agent fees and other offering expenses. The closing followed the achievement of the second closing milestone under the Company’s March 2025 securities purchase agreement, which was
- SECSurrozen Inc. filed SEC Form 8-K: Other Events8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaFirst patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bi
- PRSurrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaSOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody, for the treatment of diabetic macular edema (DME). "We believe SZN-8141 has the potential to offer a differentiated approach to retinal vascular dis
- PRSurrozen to Present at Upcoming Healthcare Investor ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences. 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 Fireside Chat at 6:10 AM Pacific Time/9:10 AM Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 Fireside Chat at 10:50 AM Pacific Time/1:50 PM Eastern Time In
- ANALYSTWilliam Blair initiated coverage on Surrozen with a new price targetWilliam Blair initiated coverage of Surrozen with a rating of Outperform and set a new price target of $51.00
- SECSEC Form 25-NSE filed by Surrozen Inc.25-NSE - Surrozen, Inc./DE (0001824893) (Subject)
- SECSEC Form 10-Q filed by Surrozen Inc.10-Q - Surrozen, Inc./DE (0001824893) (Filer)
- SECSurrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen Reports Second Quarter 2026 Financial Results and Provides Business UpdatePlanned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post-grant review petition challenging Surrozen patent SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the secon
- INSIDERLarge owner Tcg Crossover Gp Ii, Llc sold $6,906,250 worth of shares (325,000 units at $21.25) (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- PRSurrozen to Present at Upcoming Healthcare Investor ConferenceSOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026Fireside Chat at 10:00 AM Pacific Time/1:00 PM Eastern Time Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surr
- INSIDERChief Financial Officer Maleki Andrew Pedrum was granted 607 shares (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERExec. Vice President, Research Li Yang was granted 1,666 shares, increasing direct ownership by 10% to 18,882 units (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERChief Operating Officer Williams Charles O was granted 1,666 shares, increasing direct ownership by 10% to 18,237 units (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERChief Executive Officer Parker Craig C was granted 1,622 shares, increasing direct ownership by 10% to 18,175 units (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Kutzkey Tim4 - Surrozen, Inc./DE (0001824893) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- INSIDERSEC Form 4 filed by Director Rothenberg Mace4 - Surrozen, Inc./DE (0001824893) (Issuer)
SRZN FAQ
10 questionsWhat does Surrozen Inc. do?
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific...What is the latest news on SRZN?
In the last 30 days Quantisnow tracked 5 wire items for SRZN: 2 insider trades, 1 offering, 1 SEC filing and 1 press release or news item. The most recent was published on October 22, 2026.What is SRZN revenue?
Surrozen Inc. (SRZN) reported $11.51M of revenue for the twelve months ended Jun 30, 2026. That is down 8.8% from the year before. Revenue for fiscal 2025 was $3.48M.Is SRZN profitable?
No. Surrozen Inc. reported a net loss of $332.13M for the twelve months ended Jun 30, 2026.How much cash and debt does SRZN have?
Surrozen Inc. reported $102.04M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SRZN stock trade?
Surrozen Inc. (SRZN) is listed on NASDAQ.What sector and industry is SRZN in?
Surrozen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about SRZN?
Across the last 8 analyst actions on Surrozen Inc., there was 1 upgrade and 0 downgrades. The most recent action was from William Blair: Outperform with a $51.00 price target on 2026-08-20. Recent price targets range from $11.00 to $51.00.What companies are similar to SRZN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SRZN side-by-side with any of them on Quantisnow.How can I track SRZN on Quantisnow?
Quantisnow aggregates Surrozen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRZN to receive live email and push alerts on every new disclosure.